Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0029463 (
osteosarcoma
)
16,637
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
BACKGROUND
Monocarboxylate transporter 4
(
MCT4
) is a critical element for glycolytic metabolism and malignant behaviors in many tumor cells. This study aimed to determine the expression level of
MCT4
protein and its prognostic value in
osteosarcoma
. MATERIAL AND METHODS
MCT4
expression was detected via immunohistochemical and Western blot analysis for 100
osteosarcoma
patients. The correlation between
MCT4
expression and clinical factors among the patients was analyzed using the chi-square test. Overall survival of
osteosarcoma
patients was estimated by Kaplan-Meier analysis. The prognostic value of
MCT4
was evaluated using Cox regression analysis with adjustments for clinicopathological variables. RESULTS
MCT4
expression was significantly upregulated in
osteosarcoma
tissues compared with that in adjacent normal ones, detected via both immunohistochemical and Western blot analyses. High
MCT4
expression showed a positive association with distant metastasis (P=0.000) and recurrence (P=0.000) of
osteosarcoma
. Kaplan-Meier analysis indicated that overall survival of
osteosarcoma
patients was significantly higher in the low
MCT4
expression group than in the high expression group (log-rank test, P<0.001). Multivariate analysis indicated that
MCT4
expression and clinical stage, which are tightly related to the prognosis of
osteosarcoma
, might be independent predictors of
osteosarcoma
prognosis. CONCLUSIONS High
MCT4
expression appears to contribute to
osteosarcoma
progression and the upregulation of
MCT4
may predict poor prognosis among
osteosarcoma
patients.
...
PMID:Monocarboxylate Transporter 4 (MCT4) Overexpression Is Correlated with Poor Prognosis of Osteosarcoma. 3117 63
